Your prediction
Takeda Pharmaceutical Co Ltd Stock
Takeda Pharmaceutical Co Ltd gained 1.050% today.
Our community identified positive and negative aspects for Takeda Pharmaceutical Co Ltd stock for the coming years. 1 users see the criterium "Business model" as a plus for the Takeda Pharmaceutical Co Ltd stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Takeda Pharmaceutical Co Ltd in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Takeda Pharmaceutical Co Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 1.050% | 1.481% | 2.551% | 22.911% | 15.340% | 7.948% | 7.640% |
| Santen Pharmaceutical Corp Ltd. | 1.000% | -4.717% | -15.126% | 5.759% | 16.092% | 23.926% | -10.619% |
| Chugai Pharmaceutical Co Ltd | 0.730% | 1.997% | -5.665% | 11.373% | -16.019% | 41.045% | 23.007% |
| Eisai Co Ltd | 3.140% | 3.444% | 15.465% | 6.358% | 3.647% | -55.188% | -61.696% |
Comments
News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook